Real-World Studies
Hospital HTA Model Evaluates IV-to-Subcutaneous Oncology Monoclonal Antibody Transitions
Zorzetto et alInternational Journal of Technology Assessment in Health Care
Subcutaneous (SC) formulations of monoclonal antibodies (mAbs) offer faster, less invasive administration compared to traditional intravenous (IV) infusions while maintaining comparable clinical efficacy and safety profiles. To evaluate the broader organizational and financial ramifications, researchers developed a hospital-based health technology assessment (HTA) framework utilizing real-world data from a high-volume oncology center prior to price renegotiations.
The multidisciplinary scenario model accounted for drug acquisition costs, pharmacy preparation, nursing administration, chair occupancy, and staff time, incorporating Time-Driven Activity-Based Costing (TDABC) to evaluate preparation expenses. Evaluating two distinct monoclonal antibodies (mAb X and mAb Y) identified via institutional registries, investigators modeled the operational impact of transitioning from IV to SC administration across both partial and complete adoption scenarios.
The evaluation revealed meaningful expansions in institutional throughput alongside net increases in overall healthcare expenditure driven by drug acquisition costs. For antibody X, complete SC transition boosted treatment capacity by approximately 36%, despite an additional drug expenditure of €123,354 and a net budget impact of €66,778. For antibody Y, complete SC adoption increased treatment capacity by approximately 19%, with an incremental drug cost of €42,473 and a final budget impact of €6,671. These results underscore that while SC transitions relieve infusion chair congestion and enhance capacity, efficiency gains depend heavily on clinical context and deliver the greatest return in settings constrained by unmet or latent capacity demand.
Key Takeaways
- Transitioning fully from intravenous to subcutaneous administration of monoclonal antibody X expanded annual oncology treatment capacity by approximately 36%, accompanied by €123,354 in additional drug acquisition expenditure and an overall budget impact of €66,778.
- Complete subcutaneous conversion for monoclonal antibody Y increased treatment capacity by approximately 19%, requiring €42,473 in additional drug acquisition costs with a total net budget impact of €6,671.
- Efficiency gains and resource optimization derived from intravenous-to-subcutaneous switches were context-dependent, providing maximal clinical and operational benefit in centers with latent capacity demand.
Read the original sourceInternational Journal of Technology Assessment in Health Care
